ÂÜÀòÂÒÂ×

Dr. Luke is the Director of the UPMC Hillman Cancer Center (HCC) - Cancer Immunotherapeutics Center and an Associate Professor of Medicine at the University of Pittsburgh. Dr. Luke specializes in early phase drug development for solid tumors (particularly novel immunotherapeutics and biomarkers of immunotherapy activity) as well as the management of cutaneous oncology and melanoma. Dr. Luke directs the Translational Immuno-Informatics Laboratory which investigates large-scale informatics approaches to advance cancer immunotherapy. Dr. Luke is an active internationally recognized translational investigator leveraging work from his laboratory into more than 10 investigator-initiated, NCI CTEP and/or cooperative group clinical trials and acting as the international PI on registration intent industry studies. Some of these studies have changed the standard of care and are cited in the National Comprehensive Cancer Network guidelines. Dr. Luke is currently supported by a DOD award and is co-PI for the HCC UM1 NCI Phase 1 grant. Dr. Luke received his M.D. from Rosalind Franklin University of Medicine and Science in Chicago and trained at Boston University Medical Center (Medicine) as well as Weill Cornell Medical College and Memorial Sloan-Kettering Cancer Center in New York City (Medical Oncology). Dr. Luke has held prior tenure-track faculty positions at Harvard Medical School and the Dana-Farber Cancer Institute as well as the University of Chicago.